Monitoring Disease Response

摘要: Most CML patients will receive imatinib as first-line therapy. For these serial analysis of BCR-ABL blood levels by real time quantitative PCR (RQ-PCR) provides the most accurate and clinically relevant monitoring strategy. The major advantage RQ-PCR is ability to accurately frequently monitor decline in transcript level over a 4–5 log range using peripheral blood. This an early indication cases that response has been adequate minimize risk disease progression. In suboptimal responders, assay warning resistance. Frequent on should form basis clinical monitoring. Marrow cytogenetics can provide additional information some but its value quite limited who achieve maintain molecular response. development second-generation kinase inhibitors increased importance identifying cause Many, not all, domain mutations are sensitive new inhibitors. Precise be used trigger test for mutations. High-quality imatinib-treated essential maximize benefits.